GlassScriptPhysician profile
Ronald J Bell
NPI 1619910874
$17,108.62
in general payments reported to CMS, 2019-2025
67 companies · $2,961 in 2025
The $2,961 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,207 · 2020: $2,247 · 2021: $2,466 · 2022: $2,667 · 2023: $2,232 · 2024: $2,330 · 2025: $2,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,467 · Education: $55.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,467.08 |
| Education | $55.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $2,345.06 | 2019-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $1,165.35 | 2019-2025 | |
| Abbvie INC. | $1,036.00 | 2019-2025 | Ubrelvy, Qulipta, Duopa |
| Biogen, INC. | $880.90 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $660.29 | 2019-2024 | Rystiggo, Briviact, Fintepla |
| Acadia Pharmaceuticals INC | $635.01 | 2019-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $623.10 | 2019-2025 | Ultomiris |
| Grifols USA, LLC | $591.58 | 2019-2025 | Gamunex-C |
| Genzyme Corporation | $583.59 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $547.35 | 2019-2022 | |
| Amgen INC. | $474.82 | 2019-2025 | Repatha, Uplizna |
| Celgene Corporation | $461.44 | 2022-2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $403.42 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $386.09 | 2020-2025 | Rytary, Crexont |
| Vanda Pharmaceuticals INC. | $357.39 | 2024-2025 | Ponvory |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.